475085-57-5

Basic information

• Product Name: [4-[(5,6-DIPHENYLPYRAZINYL)(1-METHYLETHYL)AMINO]BUTOXY]-ACETIC ACID
• Synonyms: [4-[(5,6-DIPHENYLPYRAZINYL)(1-METHYLETHYL)AMINO]BUTOXY]-ACETIC ACID;MRE-269;ACT 333679;2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid;Selexipag Active Metabolite (ACT-333679);{4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic acid
• CAS NO: 475085-57-5
• Molecular Formula: C₂₅H₂₉N₃O₃
• Molecular Weight: 419.51606
• Mol File: 475085-57-5.mol

Chemical Properties

• Boiling Point: 602.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.160
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 3.51±0.10(Predicted)
• CAS DataBase Reference: [4-[(5,6-DIPHENYLPYRAZINYL)(1-METHYLETHYL)AMINO]BUTOXY]-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: [4-[(5,6-DIPHENYLPYRAZINYL)(1-METHYLETHYL)AMINO]BUTOXY]-ACETIC ACID(475085-57-5)
• EPA Substance Registry System: [4-[(5,6-DIPHENYLPYRAZINYL)(1-METHYLETHYL)AMINO]BUTOXY]-ACETIC ACID(475085-57-5)

Safety Data

• Hazardous Substances Data: 475085-57-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid is used as a pharmaceutical agent for its potential therapeutic effects. Given its structural features, it may interact with specific biological targets, such as receptors or enzymes, to modulate physiological processes or treat diseases.
Used in Chemical Research:
In the field of chemical research, [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid serves as a compound of interest for studying its reactivity, stability, and potential to form new derivatives. Its unique structure may lead to the discovery of novel chemical reactions or be used as a building block for the synthesis of more complex molecules.
Used in Drug Development:
[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid is utilized in drug development as a lead compound. Its specific interactions with biological systems can be further optimized to enhance its potency, selectivity, and pharmacokinetic properties, making it a promising candidate for the development of new medications.

Upstream product

• 18591-57-6 2,3-Diphenyl-6-hydroxypyrazine 
• 134-81-6 benzil 
• 475086-01-2 Selexipag 
• 39099-23-5 N-isopropyl-N-butylamine 
• 243472-70-0 2-bromo-5,6-diphenylpyrazine 
• 101727-15-5 2-iodo-5,6,-diphenylpyrazine 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 
• 18591-57-6 5,6-diphenyl-2-hydroxypyrazine 
• 41270-66-0 2-chloro-5,6-diphenylpyrazine 
• 475084-96-9 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butyl ester 

Downstream Products

• 475086-01-2 Selexipag 
• 475086-02-3 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(p-toluenesulfonyl)acetamide 
• 475086-22-7 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butoxy}-N-(dimethylaminosulfonyl)acetamide 

Relevant articles and documents

Preparation method of medical intermediate

The invention provides a preparation method of a medical intermediate 2 - {4 - [(5, 6 - diphenylpyrazine -2 -yl) (propane -2 -yl) amino] butoxy} acetate. The crystallization method uses a mixed solvent composed of a hydrocarbon and an alcohol, the hydroca

Synthesis method of diphenyl pyrazine derivative

The invention discloses a synthesis method of a diphenyl pyrazine derivative. The method is characterized in that benzil and glycinamide are used as raw materials, and a target product is prepared through five-step reaction. The obtained target product is high in purity, subsequent production of high-quality drugs is facilitated, and the synthesis method is reasonable in route design, mild in reaction condition, free of high-temperature reaction, good in safety and high in feasibility.

POLYMORPHIC FORMS AND AMORPHOUS SOLID DISPERSION OF SELEXIPAG

The present disclosure relates to crystalline forms of selexipag and their processes for preparation. The present disclosure also relates to an amorphous solid dispersion of selexipag and its processes for their preparation as well as premix of crystalline selexipag and their process.

METHOD FOR PREPARING PROSTACYCLIN RECEPTOR AGONIST

The present invention relates to preparation methods of a prostacyclin receptor agonist of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and its intermediates. These methods are simple and convenient to operate, environment-friendly and suitable for industrial production to obtain the product with good yield and high purity.

PROCESS FOR THE PREPARATION OF SELEXIPAG AND INTERMEDIATES THEREOF

The present invention provides processes for the preparation of Selexipag compound of formula (1). The present invention also provides processes for the preparation of 4-[(5,6-diphenyl-pyrazin-2-yl)-isopropyl -amino]-butan-1-ol (2), and 4-isopropylamino-butan-1-ol of formula (3), which are intermediates for the synthesis of Selexipag (1 ).

AN IMRPOVED PROCESS FOR THE PREPARATION OF SELEXIPAG OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention provides an improved process for Selexipag of formula (I) or its pharmaceutically acceptable salts.

PROCESS FOR THE PREPARATION OF DIPHENYLPYRAZINE DERIVATIVES

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

Preparation method for therapeutic drug selexipag for treating pulmonary arterial hypertension of adults

The invention discloses a preparation method for therapeutic drug selexipag for treating pulmonary arterial hypertension of adults. The therapeutic drug selexipag for treating pulmonary arterial hypertension of adults is prepared through 5-step reaction of starting materials 5-chlorine-2 and 3-diphenyl pyrazine. The invention aims to overcome the defect of higher cost of the present method, shorten the preparation process and provide the preparation method for the therapeutic drug selexipag for treating pulmonary arterial hypertension of adults that is mild in reaction, easy in operation and high in chiral purity.

High-purity match le xipa (by machine translation)

The invention discloses a high-purity match le xipa. By the match le xipa key intermediate 2 - (4 - ((5, 6 - diphenyl pyrazine - 2 - yl) isopropyl amino) butoxy) acetic acid in the organic solvent with the CDI, a sulfonamide in the organic base under the conditions of the reaction. The reaction operation is simple, low cost, environment-friendly, yield>95%, it is suitable for industrial production, the purity of the prepared match le xipa ≥ 99.9%, can better meet the requirements of drug production. The invention prepared match le xipa high purity, thereby facilitating the subsequent more high-quality drugs. (by machine translation)